The largest database of trusted experimental protocols

21 protocols using go6983

1

Pharmacological Interventions in Ischemic Stroke

Check if the same lab product or an alternative is used in the 5 most similar protocols
A438079 (P2X7 antagonist), Go6983 (PKC inhibitor), or BAPTA (intracellular Ca2+ chelator) was purchased from Tocris Bioscience (Bristol, UK). ATP, BzATP, Phorbol 12-myristate 13-acetate (PMA, PKC activator), apocynin (NADPH oxidase inhibitor), Trolox (ROS scavenger), or apyrase were purchased from Sigma Aldrich (St. Louis, MO, USA). ATP (5~50 mg/kg), BzATP (5 mg/kg), apyrase (0.2 U/kg) were administered intravenously in 0.3 mL PBS, and apocynin (2.5 mg/kg) or Trolox (2.5 mg/kg) was dissolved in DMSO and administered intravenously in 0.3 mL PBS after 9 h of pMCAO.
+ Open protocol
+ Expand
2

Characterization of Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isoproterenol, formoterol, GO6983, GO6976, RO32–0432, GF109203X, H89, PSB603, ESI-09, TPPB, NECA (adenosine-5′-N-ethyluronamide), MRS5698 and MRS2365 ([[(1R,2R,3S,4R,5S)-4-[6-amino-2-(methylthio)-9H-purin-9-yl]-2,3-dihydroxybicyclo[3.1.0]hex-1-yl]methyl] diphosphoric acid monoester trisodium salt) were purchased from Tocris (Ellisville, MO). CGS21680">CGS21680, carbachol, cholera toxin (CTX) and PTX were from Sigma (St. Louis, MO). YM254890, enzastaurin, LY333531, VTX-27 and AB928 were purchased from MedChemExpress (Monmouth Junction, NJ, USA). BAY60-6583 (LUF6210, termed hereafter ‘BAY’) was synthesized at Leiden/Amsterdam Center for Drug Research and was provided by Ad IJzerman (Leiden, The Netherlands). All compounds were dissolved in DMSO except that CTX and PTX were in water, and proper controls were included in all experiments. AlphaScreen cAMP kit, SureFire p-ERK1/2 (Thr202/Tyr204) Assay Kit and AlphaScreen SureFire p-Akt 1/2/3 (p-Ser473) Assay Kit were purchased from PerkinElmer (Waltham, MA). Gs-null and Gq/11-null HEK293 cells were generated at Tohoku University, Sendai, Japan. HEK293 human embryonic kidney, PC-3 human prostate cancer, NIH-3T3 mouse fibroblast, and H9C2 rat cardiomyoblast cells were from ATCC (Manassas, VA); all other reagents were from standard commercial sources and of analytical grade.
+ Open protocol
+ Expand
3

Investigating IL-10 mRNA Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
HNE with 81 U/mg of activity was purchased
from SERVA Electrophoresis (Heidelberg, Germany).
3,4,5-trimethoxybenzoic acid 8-(diethylamino)
octyl ester (TMB-8, Sigma-Aldrich,
Canada), A23187 (Santa Cruz Biotechnology,
USA), Rottlerin Tumor necrosis factor-alpha
(TNF-α)protease inhibitor I (TAPI-1), U73122,
R59022 (Merck Millipore, USA), and pyrrolidinedithiocarbamate
(PDTC, BioVision, USA)
were employed to investigate the intracellular
signal transduction pathways involved in IL-10
mRNA expression. The actions of these reagents
are summarized in table 1.
In addition, PKC inhibitors including Ro-
318425 (Merck Millipore), Go 6976, Go 6983,
and CGP 41251 (Tocris Bioscience, UK), as
well as a PKC theta/delta inhibitor (Merck Millipore)
were utilized to investigate the roles of
PKC isoforms in IL-10 production. The PKC
isoform-specific inhibition profile of these reagents
is summarized in table 2.
Xestospongin C, which antagonizes the calciumreleasing
action of IP3 at the receptor level, was
obtained from Sigma-Aldrich, USA. Each reagent
solution was negative for endotoxin according to
the Endospecy test (22 (link), 23 (link)).
+ Open protocol
+ Expand
4

Pharmacological Agents in Experimental Study

Check if the same lab product or an alternative is used in the 5 most similar protocols
GFX, Go6976 and Go6983 were purchased from Tocris Bioscience (Bristol, UK). All other drugs and chemicals used in this study were obtained from Sigma-Aldrich (St. Louis, MO, USA). Phenylephrine, Acetylcholine, catalase and Y27632 were dissolved in water. DMSO solvent was used in all other drugs included plumbagin. Stock solutions of drugs dissolved in DMSO in the bath never exceeded 0.01%.
+ Open protocol
+ Expand
5

Palmitic Acid and Lipid Modulation in HUVECs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human umbilical vein endothelial cells (HUVECs, from Lonza) were cultured in EGM2 (Lonza). Cell were used at the passage between 7-9. Palmitic acid (PA) (0.2 mmol/L) was prepared as previously described46 (link) was used to treated HUVECs for 30 mins (in Figures 4H and 4K) or indicated time (as illustrated in Figures 4I and 4J). Linoleic Acid-Oleic Acid-Albumin (LA+OA) (Sigma) was added at indicated time within 48 h with concentration of 260 μmol/L (in Figure S6C) or for 12 h at indicated concentrations (as illustrated in Figure S6D). Equal volume/concentration of BSA was used as control. Go6983 (1 μmol/L) and GF109203X (5 μmol/L) were from Tocris. GF109203X (5 μmol/L) was added at 30 mins before PA or LA+OA treatment. For tube formation, HUVECs were plated on solidified growth factor reduced Matrigel (Corning) in EGM2 at 5 × 104/well in 48-well plate for 12 h. Images were taken with upright phase contrast microscope (IX83, Olympus). For knockdown of SMAD4 in HUVECs, lentiviral PLKO.1 vector (GeneChem, Shanghai) carrying 4 shRNA sequences targeting human SMAD4 mRNA was co-transfected with psPAX2 and pMD2.G plasmid into HEK293FT cells. 48 h post-transfection, culture medium was collected for purification of recombinant lentivirus released from HEK293FT cells. Concentrated lentivirus was added to HUVECs at passage 4.
+ Open protocol
+ Expand
6

Synthesis and Characterization of LJO-328 Compound

Check if the same lab product or an alternative is used in the 5 most similar protocols
N -(4-tert-butylbenzyl)- N -(1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl)thiourea (LJO-328) was provided by J. Lee of Seoul National University. The structure has been published.29 (link) 2-Mercaptoethanol, n -vanillylnonanamide (nonivamide; a capsaicin analog), allyl isothiocyanate (AITC), ionomycin calcium salt, and phorbol 12-myristate 13-acetate (PMA) were from Sigma-Aldrich. Dimethyl sulfoxide (DMSO) was from Fisher Scientific. BMS-345541 and Go6983 were from Tocris, and recombinant human tumor necrosis factor-alpha ( TNFα ), interleukin-1 alpha ( IL1α ), IL1β , IL6, and IL13 were from Peprotech. 4-(4-Fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole (PD169316) was from Cayman Chemical.
+ Open protocol
+ Expand
7

Modulation of Epithelial Barrier Function

Check if the same lab product or an alternative is used in the 5 most similar protocols
NHU cells from 2 donors were cultured in triplicate and differentiated as described above. Cells from each culture were seeded onto 1.13 cm2 ThinCert® membranes (6 technical replicates per culture) as described, supplementing the differentiating medium with either 100 nM [32 (link)] pan-Protein Kinase C (PKC) inhibitor Go6983 (Tocris Bioscience, Avon, UK), or 100 nM [34 (link)] Translocator Protein (TSPO) inhibitor PK11195 (Tocris). Cultures were monitored for TEER, restitution of barrier after scratch-wounding, and rate of wound closure as mentioned above.
+ Open protocol
+ Expand
8

Ubiquitination of AMPAR Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The ubiquitination of AMPARs was induced by incubating neurons in artificial cerebrospinal fluid (ACSF; in mM, 25 HEPES, 120 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2, 30 D-glucose, pH 7.4) containing 40 μM bicuculline (Abcam) or 1 μM PMA (phorbol 12-myristate 13-acetate, Sigma) for 10 min at 37°C. In some experiments, neurons were pre-incubated with 1 μM PMA for 10 min prior to bicuculline treatment. For experiments involving the PKC blocker, neurons were pre-treated with 1 μM Go-6983 (Tocris) or DMSO (vehicle control) for 10 min prior to and present throughout the bicuculline or PMA/bicuculline treatments. Neurons were then lysed in warm 1% SDS (in PBS) and diluted in 10 volumes of ice-cold cell lysis buffer (1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 5 mM Na-pyrophosphate in PBS) supplemented with 10 mM NEM (N-ethylmaleimide, Sigma) and Complete EDTA-free protease inhibitor cocktails (Roche). Lysates were centrifuged at 14,000 rpm for 20 min at 4°C and cleared with protein A- or G-Sepharose beads. Pre-cleared lysates were then incubated with antibodies (anti-ubiquitin or anti-GFP) coupled to protein A- or G-Sepharose overnight at 4 °C, followed by four washes with ice-cold lysis buffer and elution in 2× SDS sample buffer. The immunoprecipitated proteins were resolved by SDS-PAGE and probed by western blot analysis with specific antibodies against GluA1, GluA2 and ubiquitin.
+ Open protocol
+ Expand
9

Investigating Small Molecule Modulators

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were stimulated with PD184352 (Sigma-Aldrich), prostratin (Sigma-Aldrich), ingenol,3,20-dibenzoate (Enzo LifeSciences), L690,330 (Tocris), fluticasone propionate (Sigma), or Go6983 (Tocris) dissolved in dimethylsulfoxide (DMSO) or water (for L690,330). An equal amount of the vehicle (1:1,000) was used as solvent control.
+ Open protocol
+ Expand
10

Pharmacological Modulation of Cellular Processes

Check if the same lab product or an alternative is used in the 5 most similar protocols
For most experiments, VPA (Tocris, Sigma-Aldrich) was used at a concentration of 1 mM, except when mentioned otherwise (VPA dose-dependence, Fig. 2C, D; VPA-injection into pregnant mice, Figs. S4 and S6). Other drugs used in this study included TSA (Tocris), CI994 (Selleckchem), Nicotinamide (Tocris), GO6983 (Tocris), VPD (Sigma-Aldrich), CHIR99021 (Tocris), SB216763 (Tocris), SB415286 (Tocris), myo-inositol (Sigma), KYP2047 (Sigma), PD98059 (Tocris), FR180204 (Tocris), and SP600125 (Tocris). For all experimental procedures, relevant drug concentrations and treatment protocols were described in the figure legends. In control conditions, cells were treated with equal volumes of dH2O or DMSO.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!